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BACKGROUND: We modelled the efficiency of a personalised approach to screening for prostate and breast cancer based on age and
polygenic risk-profile compared with the standard approach based on age alone.
METHODS: We compared the number of cases potentially detectable by screening in a population undergoing personalised screening
with a population undergoing screening based on age alone. Polygenic disease risk was assumed to have a log-normal relative risk
distribution predicted for the currently known prostate or breast cancer susceptibility variants (N¼31 and N¼18, respectively).
RESULTS: Compared with screening men based on age alone (aged 55–79: 10-year absolute risk X2%), personalised screening of men
age 45–79 at the same risk threshold would result in 16% fewer men being eligible for screening at a cost of 3% fewer
screen-detectable cases, but with added benefit of detecting additional cases in younger men at high risk. Similarly, compared with
screening women based on age alone (aged 47–79: 10-year absolute risk X2.5%), personalised screening of women age 35–79 at
the same risk threshold would result in 24% fewer women being eligible for screening at a cost of 14% fewer screen-detectable cases.
CONCLUSION: Personalised screening approach could improve the efficiency of screening programmes. This has potential implications
on informing public health policy on cancer screening.
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The benefits of any cancer screening programme may be offset by
adverse consequences, such as false-positive findings (positive
screening findings that do not result in a diagnosis of cancer),
overdiagnosis (diagnosis of a cancer as a result of screening that
would not have been diagnosed in a person’s lifetime had
screening not taken place) (Paci et al, 2004), and overtreatment.
A screening programme becomes viable if it does more good than
harm at reasonable cost (Gray et al, 2008).
Prostate and breast cancers are the two most commonly
diagnosed cancers in men and women, respectively, in the Western
countries (Parkin et al, 2005). The value of screening for prostate
cancer using serum prostate-specific antigen (PSA) remains
controversial even after the publication of the two major
randomised controlled trials of screening (Andriole et al, 2009;
Schroder et al, 2009). Early detection of prostate cancer by
screening can prevent death for a subset of men, but overdiagnosis
and overtreatment may be substantial. The European Study of
Screening for Prostate Cancer showed that to prevent one death
from prostate cancer, 1410 men would need to be screened and 48
would need treatment (Schroder et al, 2009), although more
mature data may demonstrate greater effectiveness. In all, 8 out of
1000 men undertaking PSA testing are likely to be overdiagnosed
(Pashayan et al, 2009). In breast cancer, the benefit of mammo-
graphic screening in preventing death is greater than the harm in
terms of overdiagnosis. On the basis of the UK Breast Screening
Programme, 2.3 out of 1000 women screened for 20 years are likely
to be overdiagnosed (Duffy et al, 2010).
Genome-wide association studies (GWAS) have identified
genetic variants that are common in the population and confer
susceptibility to different types of cancers. Most susceptibility
variants identified by GWAS in different cancers have low effect
size (per-allele relative risks of 1.1–1.3) (Chung et al, 2010) and so
the clinical utility of the individual variants in predicting future
risk is limited. However, the combination of multiple risk alleles,
each with a weak effect may result in a distribution of risk in the
population that is sufficiently wide to be clinically useful (Pharoah
et al, 2002).
Several studies have shown that risk-profiles based on the
known common susceptibility alleles have limited discrimination
for breast cancer (Gail, 2008; Pharoah et al, 2008; Wacholder et al,
2010) and for prostate cancer (Salinas et al, 2009), leading some
investigators to conclude that the clinical utility of risk prediction
based on polygenic profiling is still limited. However, discrimina-
tion is not the only measure of clinical utility of a risk prediction
model and it has been suggested that polygenic risk profiling may
provide sufficient information to enable screening for breast
cancer to be targeted to those women at highest risk (Pharoah
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set al, 2008; Devilee and Rookus, 2010; Wacholder et al, 2010). The
aim of this study was to model the efficiency of a personalised
screening strategy based on a combination of age and polygenic
risk-profile compared with a strategy based on age alone in
prostate and breast cancer.
MATERIALS AND METHODS
We compared the number of individuals eligible for screening and
the number of cases potentially detectable by screening in the
population undergoing screening based on age alone compared
with a population undergoing personalised screening based on age
and polygenic risk-profile, in which eligibility for screening
depends on 10-year absolute risk of being diagnosed with prostate
or breast cancer.
Absolute risk calculation
The number of prostate and breast cancer registrations, deaths
from prostate and breast cancer, deaths from all causes, and mid-
year population estimates in 1-year age bands for England from
2002 to 2006 were obtained from the Office for National Statistics.
These data were used to estimate prostate and breast cancer
incidence and mortality rates for prostate cancer, breast cancer,
and other causes. We then used the DevCan 6.4.1 software
(National Cancer Institute and Information Management Services,
2009) to derive the age-conditional absolute risk (risk between ages
x and y, given alive and cancer-free at age x) of being diagnosed
with prostate or breast cancer among the general population.
DevCan is based on competing risk methods developed by Fay et al
(2003). We also estimated age-conditional absolute risk for
individuals at different levels of polygenic risk by underlying
cancer-specific incidence with the polygenic relative risk.
Polygenic risk distribution
In all, 31 prostate cancer and 18 breast cancer susceptibility loci
with common risk alleles have been published (Table 1).
We estimated the variance of the distribution of polygenic risk
in the population from the published risk allele frequencies and
per-allele relative risk, assuming a log-additive model of inter-
action between risk alleles both within and between loci. Under
this model, the distribution of risk on a relative risk scale in the
population at birth is log-normal with mean, m, and variance, s
2.
We set m¼ s
2/2, so that the mean relative risk in the population
at birth is equal to unity. The distribution of relative risk among
cases at young ages is also log-normal with the same variance, but
shifted (on the log scale) to the right by s
2 (Pharoah et al, 2002).
The 31 prostate cancer susceptibility variants result in a polygenic
variance of 0.377, accounting for approximately 24% of the familial
risk of prostate cancer. The 18 breast cancer susceptibility variants
confer a polygenic variance of 0.121 and account for approximately
8.4% of the familial risk of breast cancer.
The percentile rank associated with a given polygenic relative
risk (or age-conditional absolute risk) in the population or in cases
can be calculated given the mean and variance of the log-normal
relative risk distribution. We thus estimated the proportion of the
population that has a polygenic risk greater than a given absolute
risk threshold, and the proportion of cases that will occur within
this high-risk subgroup.
We compared two approaches with screening for prostate
cancer in men aged 45–79 – screening based on age alone in which
men are only eligible for screening from age 55 (10-year absolute
risk of 2% or greater), and personalised screening in which men
are eligible for screening at a 2% absolute risk that is age and
polygenic risk dependent. We then compared the number of
individuals eligible for screening under the two approaches and
the number of cases occurring in the eligible population that are
therefore potentially screen detectable. Similarly, we compared
breast cancer screening based on age alone in women aged 47–79
(10-year absolute risk with screening X2.5%) with screening
women aged 35–79 with a 2.5% 10-year risk based on age and
polygenic profile.
RESULTS
Prostate cancer
On average, there were 22836 new cases of prostate cancer per year
in men 45–79 years in England during the period 2002 to 2006
(total population 8655126). The age-conditional absolute risk of
being diagnosed with prostate over 10 years in the general
population of men in England is shown in Figure 1. Under the
age-based screening programme, 63% of men would be eligible for
screening (aged 55 and over) and 96% of cases would occur in this
subset of the population (Table 2). These are the cases that are
potentially screen detectable. Under the personalised strategy, 53%
of men would be eligible for screening with 93 of cases being
screen detectable. Thus, the number of men eligible for screening
would be 17% fewer at a cost of detecting 3% fewer cases. For the
population of men aged 45–79 in England, there would be an
additional three screen-detectable cases per 100000 population in
men younger than 55 years of age with polygenic risk X2%, and
12 cases per 100000 population would be missed in men older than
55 years with polygenic risk o2%.
The proportion of men 45–79 years that would be eligible for
screening and the proportion of cases potentially detectable within
the eligible population at different risk thresholds are given in
Figure 2.
The eligible population for the personalised approach based on
a 1.4% 10-year risk threshold would be the same size as the age 55
and over population. The number of screen-detectable cases would
then be 0.4% (one case per 100000 population) greater under the
personalised approach. Alternatively, a 1.5% threshold for
personalised screening would be 2.6% (1637 men eligible for
screening per 100000 population) smaller than the age 55 and over
population and have the same number of screen-detectable cases.
At a higher age threshold, such as a 2.2% threshold for
personalised screening, the number eligible for screening would
be 4% (1983 per 100000 population) smaller than the age 58 and
over population and have the same number of potentially screen-
detectable cases.
Table 2 shows the eligible population and screen-detectable
cases for screening from age 51 or an absolute risk threshold of
1%, and screening from age 58 or an absolute risk threshold of 3%.
If all possible susceptibility variants for prostate cancer were
known (predicted polygenic variance 1.58), 35% of men aged
45–79 would be at 2% 10-year risk with 90% of cases being
potentially screen detectable. Compared with screening from age
55, 44% fewer men would be offered screening at a cost of 7%
fewer cases being potentially screen detectable. To detect the same
number of cases as screening from age 55, 20% (12768 men
eligible for screening per 100000 population) fewer men would be
eligible for screening (Figure 3).
Breast cancer
On average, there were 30936 new cases of breast cancer per year
in women 35–79 years in England during the period 2002–2006
(total population 13126890). The age-conditional absolute risk of
being diagnosed with breast cancer over 10 years in the general
population of women in England is given in Figure 1. Under the
age-based programme, 65% of women aged 35–79 would be
eligible for screening with 85% of cases being potentially screen
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sdetectable (Table 3). Under the personalised strategy, 50% of women
would be eligible for screening with 73 of cases being potentially
screen detectable. Thus, the number of women eligible for screening
would be 24% fewer at a cost of 14% fewer screen-detectable cases.
There would be nine screen-detectable cases per 100000 population
under personalised screening in women not eligible under age-based
screening and 38 potentially screen-detectable cases per 100000
population under age-based screening in women not eligible for
screening based on polygenic risk (Table 3).
The eligible population for the personalised approach based on
a 2.02% 10-year risk threshold would be the same size as the age 47
and over population. The number of screen-detectable cases would
then be 1% (two cases per 100000 population) greater under
the personalised approach. Alternatively, a 2% threshold for
Table 1 Common susceptibility variants for prostate and breast cancer identified through GWAS
dbSNP No. Locus/gene Risk-allele frequency Odds ratio per allele Variance Reference
Prostate
rs12621278 2q31/ITGA6 0.94 1.30 0.008 Eeles et al (2009)
rs721048 2p15 0.19 1.15 0.002 Gudmundsson et al (2008)
rs1465618 2p21/THADA 0.23 1.08 0.002 Eeles et al (2009)
rs2660753 3p12 0.11 1.18 0.002 Eeles et al (2008)
rs10934853 3q21.3 0.28 1.12 0.002 Gudmundsson et al (2009)
rs7679673 4q24 /TET2 0.55 1.09 0.004 Eeles et al (2009)
rs17021918 4q22/PDLIM5 0.66 1.10 0.003 Eeles et al (2009)
rs12500426 4q22/PDLIM6 0.46 1.08 0.007 Eeles et al (2009)
rs9364554 6q25 0.29 1.17 0.013 Eeles et al (2008)
rs6465657 7q21 0.46 1.12 0.007 Eeles et al (2008)
rs10486567 7p15 /JAZF1 0.77 1.12 0.009 Thomas et al (2008)
rs2928679 8p21 0.42 1.05 0.010 Eeles et al (2009)
rs1512268 NKX3.1 0.45 1.18 0.014 Eeles et al (2009)
rs620861 8q24 0.61 1.28 0.024 Al Olama et al (2009)
rs10086908 8q24 0.70 1.25 0.007 Al Olama et al (2009)
rs445114 8q24 0.64 1.14 0.041 Gudmundsson et al (2009)
rs16902094 8q24 0.15 1.21 0.015 Gudmundsson et al (2009)
rs6983267 8q24 0.50 1.26 0.010 Yeager et al (2007)
rs1447295 8q24 0.10 1.62 0.004 Amundadottir et al (2006)
rs16901979 8q24 0.03 2.10 0.002 Gudmundsson et al (2007a)
rs4962416 10q26 /CTBP2 0.27 1.17 0.013 Thomas et al (2008)
rs10993994 10q11/MSMB 0.24 1.25 0.014 Eeles et al (2008), Thomas et al (2008)
rs7127900 11p15 0.20 1.22 0.011 Eeles et al (2009)
rs7931342 11q13 0.51 1.16 0.012 Eeles et al (2008), Thomas et al (2008)
rs4430796 17q12 /HNF1B 0.49 1.24 0.015 Gudmundsson et al (2007b)
rs11649743 HNF1B 0.80 1.28 0.015 Sun et al (2008)
rs1859962 17q24.3 0.46 1.24 0.017 Gudmundsson et al (2007b)
rs2735839 19q13/KLK2,KLK3 0.85 1.20 0.001 Eeles et al (2008)
rs8102476 19q13.2 0.54 1.12 0.011 Gudmundsson et al (2009)
rs5759167 22q13 0.53 1.16 0.015 Eeles et al (2009)
rs5945619 Xp11 0.28 1.12 0.002 Eeles et al (2008), Gudmundsson et al (2008)
Breast
rs11249433 1p11.2 0.39 1.16 0.010 Thomas et al (2009)
rs1045485 2q33 /CASP8 0.85 1.14 0.004 Cox et al (2007)
rs13387042 2q35 0.49 1.12 0.006 Milne et al (2009)
rs4973768 3p24 /NEK10, SLC4A7 0.46 1.11 0.005 Ahmed et al (2009)
rs889312 5q11/MAP3K1 0.28 1.13 0.006 Easton et al (2007)
rs4415084 5p12/MRPS30 0.40 1.19 0.015 Stacey et al (2008)
rs2046210 6p12/ESR1 0.36 1.29 0.030 Zheng et al (2009)
rs13281615 8q24 0.40 1.08 0.003 Easton et al (2007)
rs1011970 9 0.17 1.09 0.002 Turnbull et al (2010)
rs2981582 10q26/FGFR2 0.38 1.26 0.025 Udler et al (2009)
rs2380205 10p15 0.43 0.94 0.002 Turnbull et al (2010)
rs10995190 10q21/ZNF365 0.85 1.16 0.006 Turnbull et al (2010)
rs704010 10q22 0.39 1.07 0.002 Turnbull et al (2010)
rs614367 11q13 0.15 1.15 0.005 Turnbull et al (2010)
rs3817198 11p15/LSP1 0.30 1.07 0.002 Easton et al (2007)
rs999737 14q24/RAD51L1 0.76 1.06 0.001 Thomas et al (2009)
rs1244362 16q12/TOX3 0.25 1.20 0.014 Easton et al (2007), Stacey et al (2007)
rs6504950 17q/COX11 0.73 1.05 0.001 Ahmed et al (2009)
Abbreviations: dbSNP¼Single Nucleotide Polymorphism database; GWAS¼genome-wide association study. Reported risk allele frequency in Europeans.
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Figure 1 Ten-year absolute risk of being diagnosed with prostate or
breast cancer, England, 2002–2006.
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spersonalised screening would entail screening 2% fewer women
(1477 women eligible for screening per 100000 population) than
the age 47 and over population and yield the same number of
potentially screen-detectable cases.
In a best-case scenario analysis, assuming all possible suscep-
tibility variants for breast cancer were known, 28% of women 35–79
years would be at 2.5% risk and 76% of the cases would occur in this
group. Compared with screening from age 47, 57% fewer women
would be offered screening at a cost of detecting 10% fewer cases. To
detect the same number of cases as screening from age 47, 39%
(25678 women eligible for screening per 100000 population) fewer
women would need to be screened (Figure 3).
DISCUSSION
These data show that personalised screening with eligibility for
screening based on an absolute risk that is dependent on age and
polygenic risk and equivalent to the risk threshold for eligibility
based on age alone could reduce the number of people eligible for
screening while detecting the majority of the cancers identified
through a programme based on age alone. Alternatively, screening
the same number of individuals in a personalised screening
programme could potentially detect a greater number of cases than
a screening programme based on age alone.
However, we have estimated the proportion of the population to
be offered screening and the proportion of cancer cases that might
be screen detectable in this subgroup of the population, from the
distribution of genetic risk in the population. The estimate of
potentially detectable cases is based on cancer incidence derived
from cancer registration and is independent of the detection rate
by screening. Given the normal distribution of polygenic risk
among the cases, and the number of cases in single age group, we
estimated the proportion and the expected number of cases that
will occur above a certain absolute risk threshold. We have not
estimated the expected number of cases to be detected following a
screening programme, as this would depend on screening
Table 2 Reclassification of population of 100000 men 45–79 years
eligible for screening and in whom prostate cancer could be detectable,
under age-based or personalised screening strategies
Personalised screening
Age-based screening
Polygenic risk threshold o51 years X51 years Total
Population
o1% 20355 9377 29733
X1% 2079 68188 70267
Total 22434 77566 100000
Cases
o1% 2 3 5
X1% 1 258 259
Total 3 261 264
Polygenic risk threshold o55 years X55 years Total
Population
o2% 33802 13328 47130
X2% 2841 50029 52871
Total 36643 63357 100000
Cases
o2% 6 12 18
X2% 3 243 246
Total 9 255 264
Polygenic risk threshold o58 years X58 years Total
Population
o3% 46499 16152 60408
X3% 4993 35960 39592
Total 51492 52113 100000
Cases
o3% 15 26 41
X3% 7 216 223
Total 22 242 264
Eligibility based on age or polygenic risk equivalent to 10-year absolute for that age
considering three scenarios: age 51 vs risk 1%, age 55 vs risk 2%, age 58 vs risk 3%;
England 2002–2006.
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sprogramme sensitivity. Screening programme sensitivity is the
probability of detecting cancer by screening in a population
subjected to screening. The programme sensitivity increases with
decrease in the inter-screening interval, with increase in test
sensitivity and with increase in the duration of the pre-clinical
screen-detectable phase (Launoy et al, 1998). In subjects of a given
age at high genetic risk, the test sensitivity is likely to be the same
or better than in those of the same age at low genetic risk.
However, both the PSA test (Hoffman et al, 2002) and
mammogram are less sensitive in younger subjects (at lower risk).
It is not known how test sensitivity will compare between younger
and older subjects at the same absolute risk. The duration of the
pre-clinical, screen-detectable phase may also vary by underlying
genetic risk. Thus, the comparative sensitivity of the screening
programme under the two approaches is not known, and empirical
data will be needed in order to estimate this. Assuming equivalent
or improved screening programme sensitivity, personalised
screening has the potential for cost saving as the cost of the
genetic test for risk profiling may be offset by savings on repeat
screening and diagnostic work-up of false positives.
Reducing the number of screening tests may also reduce some of
the harms associated with screening. Fewer screen tests will, at the
population level, reduce the anxiety and inconvenience associated
with having the test. Assuming that the probability of a false positive
is independent of polygenic risk-profile, reducing the number of
screen tests will also reduce the number of false-positive screens,
with a reduction in the harms associated with a false positive and the
benefit of saving further resources on diagnostic tests. Personalised
screening also has the potential to reduce the harms associated with
overdiagnosis and overtreatment, but this depends on the nature of
the relationship between polygenic risk and disease aggressiveness.
To date, there is equivocal evidence on the association of
combination of prostate cancer susceptibility variants with disease
aggressiveness (Xu et al, 2008; Bao et al, 2010).
Personalised screening may potentially confer additional benefits. It
can detect cancer in younger subjects at high risk. Prostate and breast
cancer detected in younger subjects may tend to behave more
aggressively (Fredholm et al, 2009; Lin et al, 2009). If polygenic high
risk is associated with disease aggressiveness, then potentially
additional life years would be gained by early detection of cancer in
younger subjects. The majority of breast cancer susceptibility variants
identified to date confer risk for oestrogen receptor-positive breast
cancers (Turnbull et al, 2010), which are responsive to hormonal
treatment and have a favourable prognosis (Dunnwald et al, 2007).
However, the nature of the complex interaction between disease risk,
tumour subtype, natural history of disease, and benefit from screening
are not understood and the true benefits of screening according to
genetic risk cannot be estimated.
In addition to polygenic risk, there is scope for individualised
screening based on phenotypic risk markers. Already, there is
considerable screening activity below the age range of the UK
national programme for women with a significant family history of
breast cancer (Maurice et al, 2006). There is also interest in
tailoring screening to risk based on mammographic breast density.
This might be used to prescribe screening frequency or indeed
modality, since in addition to risk, density affects the sensitivity
and the potential lead time of mammographic screening (Chiu
et al, 2010). Further studies are needed using empirical data to test
the implications of adding information on PSA test level and
family history to polygenic risk profiling for personalised screen-
ing in prostate cancer (Zheng et al, 2008).
The threshold risk for personalised screening will be population
specific. We have used data from England to estimate the
proportion of men 45–79 years that would be eligible for screening
and the proportion of cases potentially detectable within the
eligible population at different risk thresholds. The optimum
threshold risk for population of England will be different from that
of another population with different incidence of cancer, such as of
Asian population with low incidence of prostate cancer.
Other issues need to be considered. Screening based on a
personalised risk-profile would add complexity to a screening
programme. Perhaps of greater importance is the fact that
eligibility for screening based on age is generally acceptable to
both professionals and the public, but whether eligibility based on
age and other risk factors would also be acceptable is not known.
Furthermore, there are ethical and legal issues associated with
genetic testing and risk prediction that would need to be addressed
before personalised programmes could be implemented.
Personalised screening strategy based on age and genetic risk
would potentially improve the efficiency of screening programmes
and reduce their adverse consequences. Questions remain whether
higher genetic risk affects cancer detection and cancer behaviour
and so affecting test sensitivity, overdiagnosis and outcome.
Further evidence from empirical data is needed. Nevertheless, this
approach has the potential to inform public health policy decision
making in the context of population screening.
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Table 3 Reclassification of population of 10000 women 35–79 years
eligible for screening and in whom breast cancer could be detectable, under
age-based or personalised screening strategies.
Personalised screening
Age-based screening
Polygenic risk threshold o47 years X47 years Total
Population
o2.5% 30276 19926 50202
X2.5% 4429 45368 49798
Total 34705 65295 100000
Cases
o2.5% 26 38 64
X2.5% 9 162 172
Total 35 200 236
Eligibility based on age 47 or polygenic risk equivalent to 10-year absolute risk for age
47 (2.5% 10-year absolute risk); England 2002–2006.
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